FGL1 and hepatocellular carcinoma: Retrospective analysis of published datasets from studies of MASH or HCC patients (GSE48452 [34], GSE164760 [35] and GSE14520 [36]) revealed that FGL1 expression was significantly reduced in patients with MASH and HCC (Figure 6A–C).